Economic burden of antibiotic resistance: How much do we really know?

S. Gandra; D. M. Barter; R. Laxminarayan

doi:10.1111/1469-0691.12798

Economic burden of antibiotic resistance: How much do we really know?

S. Gandra, D. M. Barter, R. Laxminarayan

Research output: Contribution to journal › Review article › peer-review

190 Scopus citations

Abstract

The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual effect of antibiotic resistance on clinical outcomes is a necessary first step. In this article, we review and discuss the contributions and limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic resistance.

Original language	English (US)
Pages (from-to)	973-979
Number of pages	7
Journal	Clinical Microbiology and Infection
Volume	20
Issue number	10
DOIs	https://doi.org/10.1111/1469-0691.12798
State	Published - Oct 1 2014

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Keywords

Antibiotic resistance
Attributable morbidity and mortality
Economics

Access to Document

10.1111/1469-0691.12798

Cite this

@article{cdcc7c5e3ed24a068a60f4e775343a7c,

title = "Economic burden of antibiotic resistance: How much do we really know?",

abstract = "The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual effect of antibiotic resistance on clinical outcomes is a necessary first step. In this article, we review and discuss the contributions and limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic resistance.",

keywords = "Antibiotic resistance, Attributable morbidity and mortality, Economics",

author = "S. Gandra and Barter, {D. M.} and R. Laxminarayan",

note = "Publisher Copyright: {\textcopyright} 2014 European Society of Clinical Microbiology and Infectious Diseases.",

year = "2014",

month = oct,

day = "1",

doi = "10.1111/1469-0691.12798",

language = "English (US)",

volume = "20",

pages = "973--979",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "10",

}

TY - JOUR

T1 - Economic burden of antibiotic resistance

T2 - How much do we really know?

AU - Gandra, S.

AU - Barter, D. M.

AU - Laxminarayan, R.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual effect of antibiotic resistance on clinical outcomes is a necessary first step. In this article, we review and discuss the contributions and limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic resistance.

AB - The declining effectiveness of antibiotics imposes potentially large health and economic burdens on societies. Quantifying the economic outcomes of antibiotic resistance effectively can help policy-makers and healthcare professionals to set priorities, but determining the actual effect of antibiotic resistance on clinical outcomes is a necessary first step. In this article, we review and discuss the contributions and limitations of studies that estimate the disease burden attributable to antibiotic resistance and studies that estimate the economic burden of resistance. We also consider other factors that are important in a comprehensive approach to evaluating the economic burden of antibiotic resistance.

KW - Antibiotic resistance

KW - Attributable morbidity and mortality

KW - Economics

UR - http://www.scopus.com/inward/record.url?scp=84912531425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912531425&partnerID=8YFLogxK

U2 - 10.1111/1469-0691.12798

DO - 10.1111/1469-0691.12798

M3 - Review article

C2 - 25273968

AN - SCOPUS:84912531425

SN - 1198-743X

VL - 20

SP - 973

EP - 979

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 10

ER -

Economic burden of antibiotic resistance: How much do we really know?

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this